Wikisage, the free encyclopedia of the second generation, is digital heritage

Rufinamide: Difference between revisions

From Wikisage
Jump to navigation Jump to search
mNo edit summary
No edit summary
Line 2: Line 2:
Otsuka et al (2014) state efficacious and well tolerated AED
Otsuka et al (2014) state efficacious and well tolerated AED
<ref>[http://www.epires-journal.com/article/S0920-1211(14)00228-9/pdf  
<ref>[http://www.epires-journal.com/article/S0920-1211(14)00228-9/pdf  
Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan]</ref>
Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan]</ref>(cf.Alssad et Coren 2014) <ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256616/pdf/bcp0078-1264.pdf Exposure to rufinamide and risks of CNS adverse events in drug-resistant epilepsy: a meta-analysis of randomized, placebo-controlled trials] </ref>
<references/>
<references/>
{{Wikidata|Q}}

Revision as of 23:12, 27 January 2016

Lenox Gastaut is a low prevalence epileptic syndrome (1:10000), and Cochrane Epilepsy Group concluded that treatment remain unconcluside Otsuka et al (2014) state efficacious and well tolerated AED [1](cf.Alssad et Coren 2014) [2]

Q at Wikidata  Interwiki via Wikidata